Abstract
BACKGROUND: With the burgeoning worldwide aging population, the incidence of Alzheimer's disease (AD) and its associated disorders is continuously rising. To appraise other relevant drug targets that could lead to potent enzyme targeting, 13 previously predicted ligands (shown favorable binding with AChE (acetylcholinesterase) and GSK-3 (glycogen synthase kinase) were screened for targeting 3 different enzymes, namely butyrylcholinesterase (BChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B) to possibly meet the unmet medical need of better AD treatment. MATERIALS AND METHODS: The study utilized in silico screening of 13 ligands against BChE, MAO-A and MAOB using PyRx-Python prescription 0.8. The visualization of the active interaction of studied compounds with targeted proteins was performed by Discovery Studio 2020 (BIOVIA). RESULTS: The computational screening of studied ligands revealed the docking energies in the range of
Cite
CITATION STYLE
Jabir, N. R., Rehman, Md. T., Tabrez, S., Alserihi, R. F., AlAjmi, M. F., Khan, M. S., … Ahmed, B. A. (2021). Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer’s Treatment: A Computational Strategy. Current Pharmaceutical Design, 27(20), 2425–2434. https://doi.org/10.2174/1381612827666210226123240
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.